FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full...
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today...
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the...
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that...
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the...
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that...
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing...
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.